Remember meForgot password?
    Log in with Twitter
| Press Release

BioSyent Named to the PROFIT 500 Ranking of Canada’s Fastest-Growing Companies for Fifth Consecutive Year

TORONTO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) is pleased to announce that it has been named to the 29th annual PROFIT 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business. Published in the October issue of Maclean’s magazine and at, the PROFIT 500 ranks Canadian businesses by their five-year revenue growth.

2017 PROFIT 500 Logo
2017 PROFIT 500 Logo

Based on a five-year revenue growth rate of 538% (2011-2016), BioSyent ranked 132nd on the 2017 PROFIT 500 list. This is the fifth consecutive year that BioSyent has been named to the PROFIT 500 list and the third consecutive year that it has been ranked in the top 150 fastest-growing companies in Canada.

“We are proud to have been named to the PROFIT 500 list for the fifth consecutive year,” commented René Goehrum, President and CEO of BioSyent. “In addition to the significant growth in our revenues over the past five years, we are equally proud to have maintained consistently healthy net profit margins during this period, with our net income after tax growing by 925% from 2011 to 2016.  We remain committed to executing on our strategy of delivering the profitable growth that our shareholders have come to expect.”

“It is never easy to earn a spot on the PROFIT 500, but this year’s applicant pool was the most competitive yet,” says Deborah Aarts, PROFIT 500 program manager. “This year’s winners demonstrate the resilience, innovation and sheer management smarts it takes to build a thriving business today. Canada—and the world—needs more entrepreneurial success stories like these.”

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,478,574 shares issued and outstanding.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013

This press release may contain information or statements that are forward-looking.  The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Primary Logo